VSC Stock Overview
A biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
4SC AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €8.20 |
52 Week High | €18.10 |
52 Week Low | €2.96 |
Beta | 1.7 |
1 Month Change | 3.80% |
3 Month Change | -14.14% |
1 Year Change | 138.37% |
3 Year Change | 19.71% |
5 Year Change | -40.58% |
Change since IPO | -92.58% |
Recent News & Updates
Shareholder Returns
VSC | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -0.4% | -1.0% |
1Y | 138.4% | -24.5% | 3.0% |
Return vs Industry: VSC exceeded the German Biotechs industry which returned -24.5% over the past year.
Return vs Market: VSC exceeded the German Market which returned 3% over the past year.
Price Volatility
VSC volatility | |
---|---|
VSC Average Weekly Movement | 13.7% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: VSC has not had significant price volatility in the past 3 months.
Volatility Over Time: VSC's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 13 | Jason Loveridge | www.4sc.com |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies.
4SC AG Fundamentals Summary
VSC fundamental statistics | |
---|---|
Market cap | €76.46m |
Earnings (TTM) | -€8.24m |
Revenue (TTM) | €304.00k |
272.8x
P/S Ratio-10.1x
P/E RatioIs VSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VSC income statement (TTM) | |
---|---|
Revenue | €304.00k |
Cost of Revenue | €95.00k |
Gross Profit | €209.00k |
Other Expenses | €8.45m |
Earnings | -€8.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | -0.81 |
Gross Margin | 68.75% |
Net Profit Margin | -2,709.54% |
Debt/Equity Ratio | 61.4% |
How did VSC perform over the long term?
See historical performance and comparison